BACKGROUND: The current recommended control strategy for schistosomiasis is annual treatment using 40 mg/kg of praziquantel. However, praziquantel is only effective on adult worms and giving a second dose may increase its efficacy. We assessed the effect of one versus two doses of praziquantel on cure rate and re-infectionwith Schistosoma mansoni in a high endemic community along Lake Victoria, Uganda. METHODOLOGY: To investigate the effect of the two regimens, 395 infected people were randomised into two groups; one received a single standard dose of praziquantel (Distocide® 600 mg, Shin Poong Pharmaceuticals, Seoul, Republic of Korea), 40mg/kg body weight, while the other group received a second dose 2 weeks later. Cure rate and infection intensity were assessed 9 weeks after the first treatment using standard parasitological procedures. Re-infection levels were monitored 8 and 24 months after treatment. RESULTS: Those who received two doses were more likely to be cured (69.7%) compared to those who received a single dose (47.9%) (χ(2) = 18.5, p < 0.001). Geometric mean intensity (GMI) of infection at 9 weeks (eggs per gram of faeces [epg]) was 12.0 epg (CI95: 8.9-16.1) for individuals who received 2 doses and 22.1 epg (CI95: 16.9-28.8) for those in the single dose arm. Eight months after treatment, prevalence of re-infection for individuals in the double dose arm (61.6%, CI95: 50.2-73.1) was not significantly different from that of those in a single dose arm (68.3%, CI95: 59.9-76.8). The difference in GMI of re-infection for individuals in the single dose arm (33.8 epg, CI95: 23.2-49.3) and those in the double dose arm (34.5 epg, CI95: 24.7-48.1) was not significant. Twenty four months after treatment, prevalence of re-infection was not significantly different. The difference in GMI of re-infection for those in the single dose arm (57.5 epg, CI95: 33.9-97.5) and those in the double dose arm (42.2 epg, CI95: 29.9-59.6) was also insignificant. CONCLUSION: Our results suggest that a second dose of praziquantel given 2 weeks after the first dose improves cure rate and reduces S. mansoni infection intensity. However, there is no added advantage on reduction of S. mansoni re-infection by administering two doses of praziquantel. CLINICAL TRIALS.GOV IDENTIFIER: NCT00215267.
RCT Entities:
BACKGROUND: The current recommended control strategy for schistosomiasis is annual treatment using 40 mg/kg of praziquantel. However, praziquantel is only effective on adult worms and giving a second dose may increase its efficacy. We assessed the effect of one versus two doses of praziquantel on cure rate and re-infection with Schistosoma mansoni in a high endemic community along Lake Victoria, Uganda. METHODOLOGY: To investigate the effect of the two regimens, 395 infected people were randomised into two groups; one received a single standard dose of praziquantel (Distocide® 600 mg, Shin Poong Pharmaceuticals, Seoul, Republic of Korea), 40mg/kg body weight, while the other group received a second dose 2 weeks later. Cure rate and infection intensity were assessed 9 weeks after the first treatment using standard parasitological procedures. Re-infection levels were monitored 8 and 24 months after treatment. RESULTS: Those who received two doses were more likely to be cured (69.7%) compared to those who received a single dose (47.9%) (χ(2) = 18.5, p < 0.001). Geometric mean intensity (GMI) of infection at 9 weeks (eggs per gram of faeces [epg]) was 12.0 epg (CI95: 8.9-16.1) for individuals who received 2 doses and 22.1 epg (CI95: 16.9-28.8) for those in the single dose arm. Eight months after treatment, prevalence of re-infection for individuals in the double dose arm (61.6%, CI95: 50.2-73.1) was not significantly different from that of those in a single dose arm (68.3%, CI95: 59.9-76.8). The difference in GMI of re-infection for individuals in the single dose arm (33.8 epg, CI95: 23.2-49.3) and those in the double dose arm (34.5 epg, CI95: 24.7-48.1) was not significant. Twenty four months after treatment, prevalence of re-infection was not significantly different. The difference in GMI of re-infection for those in the single dose arm (57.5 epg, CI95: 33.9-97.5) and those in the double dose arm (42.2 epg, CI95: 29.9-59.6) was also insignificant. CONCLUSION: Our results suggest that a second dose of praziquantel given 2 weeks after the first dose improves cure rate and reduces S. mansoni infection intensity. However, there is no added advantage on reduction of S. mansoni re-infection by administering two doses of praziquantel. CLINICAL TRIALS.GOV IDENTIFIER: NCT00215267.
Authors: Matthew C Freeman; Thomas Clasen; Simon J Brooker; Daniel O Akoko; Richard Rheingans Journal: Am J Trop Med Hyg Date: 2013-09-09 Impact factor: 2.345
Authors: Stephanie M Davis; Ryan E Wiegand; Fridah Mulama; Edmund Ireri Kareko; Robert Harris; Elizabeth Ochola; Aaron M Samuels; Fredrick Rawago; Pauline M Mwinzi; LeAnne M Fox; Maurice R Odiere; Kimberly Y Won Journal: Am J Trop Med Hyg Date: 2015-03-09 Impact factor: 2.345
Authors: Marie-Astrid Hoogerwerf; Jan Pieter R Koopman; Marijke C C Langenberg; Jacqueline J Janse; Janneke Kos-van Oosterhoud; Carola Feijt; Simon P Jochems; Claudia J de Dood; Roos van Schuijlenburg; Arifa Ozir-Fazalalikhan; Mikhael D Manurung; Erliyani Sartono; Martha T van der Beek; Béatrice M F Winkel; Petra H Verbeek-Menken; Koen A Stam; Fijs W B van Leeuwen; Pauline Meij; Angela van Diepen; Lisette van Lieshout; Govert J van Dam; Paul L A M Corstjens; Cornelis H Hokke; Maria Yazdanbakhsh; Leo G Visser; Meta Roestenberg Journal: Nat Med Date: 2020-02-17 Impact factor: 53.440
Authors: Mizuho Fukushige; Kate M Mitchell; Claire D Bourke; Mark E J Woolhouse; Francisca Mutapi Journal: Front Immunol Date: 2015-02-27 Impact factor: 7.561
Authors: Narcis Kabatereine; Fiona Fleming; Wangechi Thuo; Benjamin Tinkitina; Edridah M Tukahebwa; Alan Fenwick Journal: BMC Res Notes Date: 2014-12-11
Authors: Artemis Koukounari; Christl A Donnelly; Irini Moustaki; Edridah M Tukahebwa; Narcis B Kabatereine; Shona Wilson; Joanne P Webster; André M Deelder; Birgitte J Vennervald; Govert J van Dam Journal: PLoS Comput Biol Date: 2013-12-19 Impact factor: 4.475